The National Agency for Food and Drug Administration and Control (NAFDAC) has been notified by the South African Health Products Regulatory Authority (SAPHRA) of the recall of specific batches of Citro-Soda Regular following a potential contamination risk identified at the Adcock Ingram Clayville manufacturing facility in Johannesburg.
Citro-Soda is an effervescent urinary alkalinizer and gastric antacid used to treat heartburn, indigestion, and UTI symptoms by neutralizing excess acid.
Risk Statement
The use of contaminated medicinal products poses a severe risk to public health, with the potential to cause acute toxicity, long-term health complications, or death.
Product Details
The recall is limited to Citro-Soda Regular produced at the Clayville plant. The affected products can be identified by:
- Batch Number: All batches starting with the letter “C”.
- Expiry Dates: On or before November 2027.
- Pack Sizes: Citro-Soda Regular 60g, Citro-Soda Regular 120g, Citro-Soda Regular 4g x 30 Sachets
- Product Type: Specifically, “Regular” flavour.
Product Image
It is important to stress that the recall was conducted in South Africa, and the implicated batches were produced in the Adcock Ingram Clayville manufacturing facility in Johannesburg.
All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove recalled products if found in their respective zones and states.
Importers, distributors, retailers, healthcare professionals, caregivers, and consumers are hereby advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale, and use of the recalled products. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines, medical devices, or any NAFDAC-regulated product to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
For complaints, you can call the Reforms Unit on the following lines: 09097630506, 09097630507, or email: reforms@nafdac.gov.ng
Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).
NAFDAC………. Customer-focused, Agency-minded!!!
